<PAGE>
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(MARK ONE)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 for the transition period from _______ to _______.
COMMISSION FILE NUMBER: 0-30859
CARESCIENCE, INC.
------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
PENNSYLVANIA 23-2703715
--------------------------------- -------------------
(STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER
OF INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
3600 MARKET STREET
PHILADELPHIA, PA 19104
---------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(ZIP CODE)
(215) 387-9401
----------------------------------------------------
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
----------------------------------------------------
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR,
IF CHANGED SINCE LAST REPORT)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
The number of shares of the registrant's Common Stock outstanding, as of
August 7, 2000 was 12,756,851.
<PAGE>
Page 1
CARESCIENCE INC.
FORM 10-Q
JUNE 30, 2000
INDEX
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Balance Sheets- - December 31, 1999 and June 30, 2000
(unaudited)....................................................................2
Statements of Operations- - Three and Six Months Ended June 30, 1999
and June 30, 2000 (unaudited)..................................................3
Statements of Cash Flows- - Six Months Ended June 30, 1999 and
June 30, 2000 (unaudited)......................................................4
Notes to Financial Statements..................................................5
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations......................................................7
Item 3. Quantitative and Qualitative Disclosures About Market Risk...........11
PART II. OTHER INFORMATION
Item 1. Changes in Securities and Use of Proceeds.............................12
Item 2. Exhibits and Reports on Form 8-K......................................12
<PAGE>
Page 2
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
CARESCIENCE, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>
DECEMBER 31, JUNE 30,
1999 2000
------------ ------------
(UNAUDITED) (UNAUDITED)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents .......................... $ 3,381,600 $ 885,658
Accounts receivable, net of allowance for doubtful
accounts of $29,754 and $48,794, respectively ..... 719,570 882,203
Stock subscription receivable ...................... -- 44,640,000
Prepaid expenses and other ......................... 203,957 331,748
------------ ------------
Total current assets .................................. 4,305,127 46,739,609
------------ ------------
Property and equipment:
Computer equipment ................................. 2,213,629 3,145,756
Office equipment ................................... 263,260 421,418
Furniture and fixtures ............................. 273,086 395,936
------------ ------------
2,749,975 3,963,110
Less--Accumulated depreciation and amortization .... (1,705,518) (2,043,927)
------------ ------------
Net property and equipment ....................... 1,044,457 1,919,183
------------ ------------
Total assets ................................... $ 5,349,584 $ 48,658,792
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Current portion of capital lease obligations ....... $ 317,065 $ 288,533
Accounts payable ................................... 214,263 1,271,571
Accrued expenses ................................... 397,076 1,930,555
Deferred revenues .................................. 2,923,737 3,706,764
Dividends payable under convertible preferred stock -- 1,516,784
------------ ------------
Total current liabilities ........................ 3,852,141 8,714,207
------------ ------------
Capital lease obligations ............................. 459,955 515,619
------------ ------------
Commitments and contingencies
Mandatorily redeemable preferred stock ................ 4,681,634 4,935,365
------------ ------------
Shareholders' equity (deficit):
Preferred stock, no par value, liquidation value of
$13,336,234 at December 31, 1999 ................. 12,009,700 --
Common stock, no par value, 16,000,000 shares
authorized, 4,827,900 and 14,196,851 shares issued
and 3,387,900 and 12,756,851 outstanding ......... 50,000 59,516,562
Additional paid-in capital ......................... 5,624,839 5,745,522
Deferred compensation .............................. (5,392,322) (4,832,312)
Accumulated deficit ................................ (15,036,363) (25,036,171)
Treasury stock, at cost, 1,440,000 shares .......... (900,000) (900,000)
------------ ------------
Total shareholders' equity (deficit) ............. (3,644,146) 34,493,601
------------ ------------
Total liabilities and shareholders' equity .... $ 5,349,584 $ 48,658,792
============ ============
</TABLE>
The accompanying notes are an integral part of these statements
<PAGE>
Page 3
CARESCIENCE, INC.
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
FOR THE THREE MONTHS ENDED FOR THE SIX MONTHS ENDED
JUNE 30, JUNE 30,
----------------------------- -----------------------------
1999 2000 1999 2000
----------- ----------- ----------- -----------
(UNAUDITED) (UNAUDITED)
<S> <C> <C> <C> <C>
Revenues ........................... $ 868,473 $ 1,922,055 $ 1,586,206 $ 3,550,982
Cost of revenues (excludes
stock-based compensation of $
171,045 and $341,175 for the
three and six months ended June
30, 2000) ........................ 555,303 1,148,426 1,066,218 2,174,467
----------- ----------- ----------- -----------
Gross profit ..................... 313,170 773,629 519,988 1,376,515
----------- ----------- ----------- -----------
Operating expenses:
Research and development
(excludes stock-based
compensation of $23,900 and
$46,865 for the three and six
months ended June 30, 2000) .... 357,968 806,548 753,649 1,405,672
Selling, general and
administrative (excludes
stock-based compensation of
$146,723 and $292,652 for the
three and six months ended June
30, 2000) ...................... 986,510 1,776,535 1,885,459 3,341,274
Stock-based compensation ......... -- 341,668 -- 680,692
----------- ----------- ----------- -----------
Total operating expenses ....... 1,344,478 2,924,751 2,639,108 5,427,638
----------- ----------- ----------- -----------
Operating loss ................. (1,031,308) (2,151,122) (2,119,120) (4,051,123)
Interest income .................... (41,666) (24,239) (94,853) (66,287)
Interest expense ................... 25,017 23,616 51,000 44,456
----------- ----------- ----------- -----------
Net loss ........................... (1,014,659) (2,150,499) (2,075,267) (4,029,292)
Accretion of redemption premium on
preferred stock .................. 96,396 138,360 190,714 253,731
Preference distribution on
preferred stock .................. -- 5,716,784 -- 5,716,784
----------- ----------- ----------- -----------
Net loss applicable to common
shareholders ..................... $(1,111,055) $(8,005,643) $(2,265,981) $(9,999,807)
=========== =========== =========== ===========
Net loss per common share:
Basic and diluted ................ $ (0.33) $ (2.23) $ (0.67) $ (2.86)
Weighted average shares outstanding:
Basic and diluted ................ 3,387,900 3,593,811 3,387,900 3,490,856
</TABLE>
The accompanying notes are an integral part of these statements.
<PAGE>
Page 4
CARESCIENCE, INC.
STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED
JUNE 30,
1999 2000
----------- -----------
(UNAUDITED)
Cash flows from operating activities:
Net loss .............................. $(2,075,267) $(4,029,292)
Adjustments to reconcile net loss to
net cash used in operating
activities--
Depreciation and amortization ..... 310,346 338,409
Provision for bad debts ........... 4,375 12,000
Stock-based compensation .......... -- 680,692
Changes in assets and liabilities--
(Increase) in--
Accounts receivable ............ (1,105,581) (174,633)
Prepaid expenses and other ..... (54,599) (127,790)
Increase (decrease) in--
Accounts payable and accrued
expenses ..................... (92,097) 1,324,451
Deferred revenues .............. 793,291 783,027
Net cash used in operating
activities ................ (2,219,532) (1,193,136)
----------- -----------
Cash flows from investing activities:
Purchases of property and equipment,
net ................................. (157,260) (998,263)
----------- -----------
Cash flows from financing activities:
Payments on capital lease obligations (162,718) (187,741)
Cost related to the issuance of
Common stock ..................... -- (116,802)
----------- -----------
Net cash used in financing
activities ................ (162,718) (304,543)
----------- -----------
Net decrease in cash and cash equivalents (2,539,510) (2,495,942)
Cash and cash equivalents,
beginning of period .................. 5,346,099 3,381,600
----------- -----------
Cash and cash equivalents,
end of period ........................ $ 2,806,589 $ 885,658
=========== ===========
The accompanying notes are an integral part of these statements.
<PAGE>
Page 5
CARESCIENCE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization and Basis of Presentation
CareScience, Inc. (formerly Care Management Science Corporation) provides
Internet-based tools designed to improve the quality and efficiency of health
care. The Company's products use its proprietary clinical algorithms and data
collection and storage technologies to perform complex clinical analyses. The
Company's customers use its products to identify clinical inefficiencies and
medical errors and monitor the results of implemented solutions. Additionally,
the Company facilitates the real-time exchange of clinical information over the
Internet among local health care constituents.
The balance sheet as of June 30, 2000, the statements of operations for
the three and six months ended June 30, 1999 and 2000 and the statements of cash
flows for the six months ended June 30, 1999 and 2000 have been prepared by the
Company without audit. In the opinion of management, all adjustments, consisting
of normal and recurring adjustments, necessary to present fairly the financial
position, results of operations and cash flows at June 30, 2000 and for all
periods presented have been made.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted. It is suggested that these financial
statements be read in conjunction with the financial statements and notes
thereto included in the Company's Registration Statement on Form S-1 as filed
with the Securities and Exchange Commission. The results of operations for the
three and six months ended June 30, 2000 are not necessarily indicative of the
operating results for the full year.
Supplemental Cash Flow Information
The Company paid interest of $51,000 and $44,456 for the six months ended
June 30, 1999 and 2000, respectively.
The Company financed $22,048 and $214,872 of property and equipment
purchases with capital leases for the six months ended June 30, 1999 and 2000,
respectively.
Major Customers
The Company's operations are conducted in one business segment and sales
are primarily made to health care payors and providers. The company had one
customer for each of the six month periods ended June 30, 1999 and 2000, which
accounted for 15% and 22% of total revenues.
The Company had three customers at June 30, 2000, which accounted for 35%
of total accounts receivable.
(2) INITIAL PUBLIC OFFERING
On June 28, 2000, the Company completed its initial public offering of
4,000,000 shares of Common stock at a price of $12.00 per share. The Company
received net proceeds of approximately $43.2 million from the offering. Upon the
consummation of the offering the following transactions were recorded:
<PAGE>
Page 6
- The conversion of Series C, D and E Convertible Preferred stock into
5,018,951 shares of Common stock;
- The issuance, upon the conversion of the Series C Convertible Preferred
stock, of Series F Redeemable Preferred stock, with a redemption value of
$4.2 million, and the simultaneous redemption of the Series F Redeemable
Preferred stock for 350,000 shares of Common stock;
- The accretion of the redemption value of the Series G Preferred stock
through June 2000 which was paid on July 5, 2000; and
- The declaration of a dividend of $1.5 million (calculated at 8% per annum
through July 5, 2000) paid to the Series C, D and E Preferred shareholders
from the proceeds of the Offering on July 5, 2000.
(3) NET LOSS PER SHARE
Net loss per share is calculated utilizing the principles of SFAS No. 128,
"Earnings per Share" ("EPS"). Basic EPS excludes potentially dilutive securities
and is computed by dividing net income available to common shareholders by the
weighted-average number of common shares outstanding for the period. Diluted EPS
is computed assuming the conversion or exercise of all dilutive securities such
as preferred stock, options and warrants.
Under SFAS No. 128, the Company's granting of certain stock options,
warrants and convertible preferred stock resulted in potential dilution of basic
EPS. The number of incremental shares from the assumed exercise of stock options
and warrants is calculated applying the treasury stock method. Stock options,
warrants and Preferred stock convertible into common shares were excluded from
the calculations as they were anti-dilutive due to the net loss.
(4) COMMON STOCK OPTIONS
Equity Compensation Plans
The Company's 1995 Equity Compensation Plan (the "Plan") permits the
granting of incentive stock options, nonqualified stock options, stock
appreciation rights and restricted stock. The Company has authorized the
issuance of up to 2,065,038 shares of Common stock to satisfy grants under the
Plan. At June 30, 2000, there were 561,197 shares reserved under the Plan
available for grant. A committee of the Board of Directors (the "Committee")
administers the Plan and determines the terms of the grants.
In December 1998, the Company adopted the 1998 Time Accelerated Restricted
Stock Option Plan (the "Accelerated Plan"). The Accelerated Plan provides for
the granting of non-qualified stock options to officers, senior management and
employee directors of the Company. The aggregate number of shares of Common
stock the Company may issue under the Accelerated Plan is 483,594 shares. At
June 30, 2000 there were 28,359 shares reserved under the Accelerated Plan
available for grant.
The Company accounts for all plans under APB Opinion No. 25, under which
compensation expense is recognized based on the amount by which the fair value
of the underlying common stock exceeds the exercise price of the stock options
on the measurement date. For financial reporting purposes, the Company has
determined that the deemed fair market value on the measurement date for certain
stock options was in excess of the exercise price. This amount has been recorded
as deferred compensation and is being amortized over the vesting period of the
applicable options, which range between four and seven years. The Company
recorded deferred compensation of $5,624,839 and $120,683 during the year ended
December 31, 1999 and the six months ended June 30, 2000, respectively. The
Company recognized $341,668 and $680,692 of compensation expense related to
options for the three and six months ended June 30, 2000, respectively.
<PAGE>
Page 7
The following table summarizes the option activity for both plans:
<TABLE>
<CAPTION>
OPTIONS OUTSTANDING
----------------------------------------------------
SHARES WEIGHTED
AVAILABLE NUMBER EXERCISE AVERAGE
FOR OF PRICE AGGREGATE EXERCISE
GRANT SHARES PER SHARE PRICE PRICE
---------- --------- ----------- ---------- --------
<S> <C> <C> <C> <C> <C>
Balance, December 31, 1996 ....... 488,000 126,000 $0.25- 1.25 $ 93,500 $ .74
Authorized ..................... -- -- -- -- --
Granted ........................ (163,400) 163,400 1.25 204,250 1.25
Forfeited/Canceled ............. 38,200 (38,200) 0.25- 1.25 (26,550) .70
---------- --------- ----------- ---------- ------
Balance, December 31, 1997 ....... 362,800 251,200 0.25- 1.25 271,200 1.08
Authorized ..................... 1,134,632 -- -- -- --
Granted ........................ (472,635) 472,635 1.25- 2.60 895,227 1.89
Forfeited/Canceled ............. 12,800 (12,800) 0.25- 1.25 (10,800) .84
---------- --------- ----------- ---------- ------
Balance, December 31, 1998 ....... 1,037,597 711,035 0.25- 2.60 1,155,627 1.63
Authorized ..................... -- -- -- -- --
Granted ........................ (1,108,150) 1,108,150 1.25- 2.59 2,814,164 2.54
Forfeited/Canceled ............. 216,413 (216,413) 0.25- 2.59 (291,017) 1.34
---------- --------- ----------- ---------- ------
Balance, December 31, 1999 ....... 145,860 1,602,772 0.25- 2.60 3,678,774 2.30
Authorized (unaudited) ......... 800,000 -- -- -- --
Granted (unaudited) ............ (360,617) 360,617 2.59-12.00 4,206,721 11.67
Forfeited/Canceled (unaudited).. 4,313 (4,313) 1.25- 2.59 (7,653) 1.77
---------- --------- ----------- ---------- ------
Balance, June 30, 2000 (unaudited) 589,556 1,959,076 $0.25-12.00 $7,877,842 $ 4.02
========== ========= =========== =========== ======
</TABLE>
The above table includes options granted during the six months ended June
30, 2000 at an initial public offering price of $12.00 per share.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
This report includes a number of forward-looking statements that reflect
our current views with respect to future events and financial performance. We
use words such as anticipates, believes, expects, future, and intends, and
similar expressions to identify forward-looking statements. For these statements
we claim the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995. There are
important factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements, including:
- the difficulty in evaluating our business because we operate in a new
industry and our operating history is limited;
- we have a history of losses and expect our losses to continue;
- the proprietary technology we own or license may be subjected to
infringement claims or disagreements with the licensor which could be
costly to resolve;
- we depend on an exclusive license with the University of Pennsylvania for
our technology, and the loss of this license would impair our ability to
develop our business;
- we could be liable for information retrieved from our Web sites and incur
significant costs from resulting claims;
- we may experience system failures which could interrupt our service and
damage our customer relationships;
<PAGE>
Page 8
- the health care industry may not accept our solutions or buy our products
which would adversely affect our financial results;
- because our revenues are dependent on a limited number of product lines,
the failure of any one of these product lines would significantly decrease
our revenues;
- termination of one or more of our significant contracts would cause a
significant decline in our revenue;
- failure to manage our growth would adversely affect our operations;
- we face intense competition and may be unable to compete successfully which
would adversely effect our financial results;
- the loss of any of our key personnel could adversely affect our operations;
- our failure to develop strategic relationships could adversely affect our
ability to develop new products;
- our failure to use new technologies effectively or to adapt emerging
industry standards would adversely affect our ability to compete;
- our failure to adapt our technology to our customers' needs or to handle
high levels of customer activity would adversely affect our ability to
increase revenue;
- failure of our service providers could interrupt our business and damage
our customer relationships;
- we may need to obtain additional capital and failure to do so may limit our
growth;
- health information is subject to potential government regulation and legal
uncertainties and changes may require us to alter our business;
- changes in the health care industry could adversely affect our operations;
- our business will suffer if commercial users do not accept Internet
solutions;
- our industry is evolving and we may not adapt successfully.
Overview
We released our first Internet products, CaduCIS Manager and CaduCIS Net,
in 1996. We subsequently released CaduCIS Alliance in July 1999. Since our first
product release, we have signed over $15 million in multi-year contracts with
customers for our CaduCIS products. In March 1999, we introduced our
CareStandard products, and entered into a $4.6 million contract with the
California HealthCare Foundation to develop our Care Exchange technology and
business model. We have recently entered into a $1.5 million five-year
collaboration agreement with British Biotech plc to further develop our
CareScript product which is a web based analytical tool for acquiring, managing
and evaluating clinical data in the field of oncology. We expect sales of
CareLeader and CareSense products to commence in 2001.
We generate revenues from subscriptions to our Internet-based proprietary
technology applications and hosting of customer data, as well as from training,
implementation and consulting services. We sell our products individually or as
an integrated suite of products and services. Our contacts are fixed price based
on estimates of certain variables, such as the number of a hospital's patient
admissions or outpatient visits, or the number of members enrolled in a health
plan. In the future, we may also price our products on a per-transaction basis.
Our subscription agreements typically cover an initial three-to five-year
period with provisions for automatic renewals. We recognize training and
implementation fees, as well as subscriptions and related hosting revenues, on a
pro-rata basis over the life of the contract. We recognize consulting fees as
the program or service is delivered.
Our contracts generally provide for payment in advance of services
rendered. Therefore, we record these payments as deferred revenues and recognize
these payments when earned in accordance with our
<PAGE>
Page 9
revenue recognition policy. Our deferred revenue balances were $2.9 million
and $3.7 million at December 31, 1999 and June 30, 2000, respectively.
More than 100 health care organizations subscribe to our products.
We have incurred substantial research and development costs since
inception and have also invested in our corporate infrastructure to support our
long-term growth strategy. We expect that our operating expenses will continue
to increase as we expand our product development and sales and marketing
efforts. Accordingly, we expect to continue to incur quarterly net losses for
the foreseeable future.
On June 28, 2000 we completed an initial public offering of 4,000,000
shares of Common stock at a price of $12.00 per share. We received aggregate net
cash proceeds of approximately $43.2 million from the initial public offering on
July 5, 2000.
RESULTS OF OPERATIONS
THREE MONTHS ENDED JUNE 30, 2000 AND JUNE 30, 1999
REVENUES
Total revenues increased 121% to $1.9 million for the three months ended
June 30, 2000 from $868,000 for the three months ended June 30, 1999. The
increase was primarily related to revenues generated from newly signed customer
contracts.
Unrecognized revenues related to customer contracts as of June 30, 2000
totaled $15 million.
COST OF REVENUES
Costs of revenues include customer product and service-related costs
including personnel and facility costs, depreciation and maintenance. Cost of
revenues for the three months ended June 30, 2000 was $1.1 million (excluding
stock-based compensation of $171,000), an increase of $593,000 or 107%, compared
to $555,000 for the three months ended June 30, 1999. The increase was primarily
a result of additional costs necessary to service new customers.
GROSS PROFIT
Our gross profit margin increased from 36% for the three months ended June
30, 1999, to 40% for the three months ended June 30, 2000. The increase in gross
profit margin is primarily due to increased revenues spread over a fixed cost
base.
RESEARCH AND DEVELOPMENT
Research and development costs include technology and product development
costs. Research and development costs for the three months ended June 30, 2000
were $807,000 (excluding stock-based compensation of $24,000), an increase of
$449,000 or approximately 125%, compared to $358,000 for the three months ended
June 30, 1999. This increase is primarily due to expenditures made related to
new product development.
As a percentage of revenue, research and development costs were 42% for
the three months ended June 30, 2000 as compared to 41% for the three months
ended June 30, 1999.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses include costs associated with
our sales, marketing, finance, human resource and administrative functions.
Selling, general and administrative expenses for the three months ended June 30,
2000 were $1.8 million (excluding stock-based compensation of $147,000), an
increase of $790,000, or 80% compared to $987,000 for the three months ended
June 30, 1999. The increase was primarily related to hiring of additional sales
and management personnel and marketing expenditures to increase and support
customer growth.
<PAGE>
Page 10
As a percentage of revenues, selling, general, and administrative expenses
were 92% for the three months ended June 30, 2000 as compared to 114% for the
three months ended June 30, 1999.
STOCK-BASED COMPENSATION
We granted certain stock options to our officers and employees with
exercise prices deemed to be below the fair market value of the underlying
stock. The cumulative difference between the fair value of the underlying stock
at the date the options were granted and the exercise price of the granted
options was $5.7 million at June 30, 2000. We expect to amortize this amount
over the four to seven year vesting periods of the granted options. Accordingly,
our results from operations will include stock-based compensation expense at
least through 2006. We recognized $342,000 of this expense during the three
months ended June 30, 2000.
INTEREST INCOME AND EXPENSE
Net interest income for the three months ended June 30, 2000 was $1,000, a
decrease of $15,000, or approximately 94%, compared to $16,000 for the three
months ended June 30, 1999. The decrease is primarily due to lower investable
cash balances.
SIX MONTHS ENDED JUNE 30, 2000 AND JUNE 30, 1999
REVENUES
Total revenues increased 124% to $3.6 million for the six months ended
June 30, 2000 from $1.6 for the six months ended June 30, 1999. The increase was
primarily related to revenues generated from newly signed customer contracts.
COST OF REVENUES
Costs of revenues include customer product and service-related costs
including personnel and facility costs, depreciation and maintenance. Cost of
revenues for the six months ended June 30, 2000 was $2.2 million (excluding
stock-based compensation of $341,000), an increase of $1.1 million or 104%,
compared to $1.1 million for the six months ended June 30, 1999. The increase
was primarily a result of additional costs necessary to service new customers.
GROSS PROFIT
Our gross profit margin increased from 33% for the six months ended June
30, 1999, to 39% for the six months ended June 30, 2000. The increase in gross
profit margin is primarily due to increased revenues spread over a fixed cost
base.
RESEARCH AND DEVELOPMENT
Research and development costs include technology and product development
costs. Research and development costs for the six months ended June 30, 2000
were $1.4 million (excluding stock-based compensation of $47,000), an increase
of $652,000 or approximately 87%, compared to $754,000 for the six months ended
June 30, 1999. This increase is primarily due to expenditures made related to
new product development.
As a percentage of revenue, research and development costs were 40% of
revenue for the six months ended June 30, 2000 as compared to 48% for the six
months ended June 30, 1999.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses include costs associated with
our sales, marketing, finance, human resource and administrative functions.
Selling, general and administrative expenses for the six months ended June 30,
2000 were $3.3 million (excluding stock-based compensation of $293,000); an
increase of $1.4 million, or 77% compared to $1.9 million for the six months
ended June 30, 1999. The
<PAGE>
Page 11
increase was primarily related to hiring of additional sales and management
personnel and marketing expenditures to increase and support customer
growth.
As a percentage of revenues, selling, general, and administrative expenses
were 94% for the six months ended June 30, 2000 as compared to 119% for the six
months ended June 30, 1999.
STOCK-BASED COMPENSATION
We granted certain stock options to our officers and employees with
exercise prices deemed to be below the fair market value of the underlying
stock. The cumulative difference between the fair value of the underlying stock
at the date the options were granted and the exercise price of the granted
options was $5.7 million at June 30, 2000. We expect to amortize this amount
over the four to seven year vesting periods of the granted options. Accordingly,
our results from operations will include stock-based compensation expense at
least through 2006. We recognized $681,000 of this expense during the six months
ended June 30, 2000.
INTEREST INCOME AND EXPENSE
Net interest income for the six months ended June 30, 2000 was $22,000, a
decrease of $22,000, or approximately 50%, compared to $44,000 for the six
months ended June 30, 1999. The decrease is primarily due to lower investable
cash balances.
LIQUIDITY AND CAPITAL RESOURCES - JUNE 30, 2000
Since inception, we have financed our operations and funded our capital
expenditures through the private sale of equity securities, supplemented by
private debt and equipment leases. We believe that proceeds from our initial
public offering will be sufficient to fund anticipated capital expenditures and
working capital requirement for at least the next 12 months. As of June 30,
2000, we had $886,000 in cash and working capital of $38.0 million.
Net cash used in operating activities was $1.2 million for the six months
ended June 30, 2000 and $2.2 million for the six months ended June 30, 1999. For
those periods, net cash used in operating activities was primarily to fund
losses from operations.
Net cash used in investing activities was $998,000 for the six months
ended June 30, 2000 and $157,000 for the six months ended June 30, 1999.
Investing activities consisted primarily of purchase of property and equipment.
Net cash used in financing activities was $305,000 for the six months
ended June 30, 2000 and $163,000 for the six months ended June 30, 1999.
Financing activities for these periods consisted primarily of payments on
capital lease obligations.
As we execute our strategy, we expect significant increases in our
operating expenses to fund development of current and new divisions and product
lines. Presently, we anticipate that our existing capital resources and the
proceeds from the offering will meet our operating and investing needs through
the end of 2001. After that time, additional funding may not be available on
acceptable terms or at all. If we require additional capital resources to grow
our business, execute our operating plans or acquire complementary businesses at
any time in the future, we may seek to sell additional equity or debt securities
or secure additional lines of credit, which may result in ownership dilution to
our shareholders.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Most of our cash equivalents and capital lease obligations are at fixed
interest rates and therefore the fair market value of these instruments is
affected by changes in market interest rates. As of June 30, 2000 all of our
cash equivalents matured within 1 day and we had the ability to immediately
liquidate our investments. Therefore, we believe that we are exposed to
immaterial levels of market risk.
<PAGE>
Page 12
PART II. OTHER INFORMATION
ITEM 1. CHANGES IN SECURITIES AND USE OF PROCEEDS
On June 28, 2000 the Securities and Exchange Commission declared effective
our Registration Statement on Form S-1 (File number 333-32376), relating to the
initial public offering of our Common Stock, no par value per share. The
offering commenced on June 28, 2000 and all 4,000,000 shares covered by the
Registration Statement were sold. The managing underwriters for the offering
were Deutsche Bank Securities, Inc., FleetBoston Robertson Stephens Inc. and
Thomas Weisel Partners LLC.
The aggregate gross proceeds from the offering were $48.0 million. We
incurred expenses of approximately $4.8 million, of which $3.4 million
represented underwriting discounts and commissions and approximately $1.4
million represented other expenses related to the offering. The net offering
proceeds to us after total expenses were $43.2 million. We used approximately
$5.0 million of the net proceeds to redeem our Series G Preferred stock and
approximately $1.5 million to pay accrued dividends on our Series C, D and E
Convertible Preferred stock. The remaining net proceeds have been invested in
cash, cash equivalents and short-term investments. The use of the proceeds from
the offering does not represent a material change in the use of proceeds
described in the prospectus.
None of the net proceeds from the offering were used to pay, directly or
indirectly, directors, officers, persons owning ten percent or more of the
Company's equity securities, or affiliates of the Company.
ITEM 2. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
See Exhibit Index
(b) Reports on Form 8-K
None
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CARESCIENCE, INC.
Date: August 8, 2000 By: /s/ RONALD A. PAULUS
----------------------------
Ronald A. Paulus, President
Date: August 8, 2000 By: /s/ STEVEN BELL
----------------------------
Steven Bell, Chief Financial
Officer and Treasurer
<PAGE>
Page 13
EXHIBIT INDEX
-------------
EXHIBIT NO. DESCRIPTION
----------- -----------
27.1 Financial Data Schedule
